1. Comparison of Preoperative Alpha-blockade for Resection of Paraganglioma and Pheochromocytoma.
- Author
-
Zhu CY, Hong JC, Kamdar NV, Hu MY, Tseng CH, Lee JS, Kuo EJ, Yu R, Isorena J, Yeh MW, and Livhits MJ
- Subjects
- Adrenergic alpha-Antagonists therapeutic use, Case-Control Studies, Doxazosin pharmacology, Doxazosin therapeutic use, Humans, Phenoxybenzamine pharmacology, Phenoxybenzamine therapeutic use, Phenylephrine therapeutic use, Prospective Studies, Adrenal Gland Neoplasms drug therapy, Adrenal Gland Neoplasms surgery, Pheochromocytoma drug therapy, Pheochromocytoma surgery
- Abstract
Objective: Phenoxybenzamine (nonselective, noncompetitive alpha-blocker) is the preferred drug for preoperative treatment of pheochromocytoma, but doxazosin (selective, competitive alpha-blocker) may be equally effective. We compared the efficacy of doxazosin vs phenoxybenzamine., Methods: We conducted a prospective study of patients undergoing pheochromocytoma or paraganglioma resection by randomizing pretreatment with phenoxybenzamine or doxazosin at a single tertiary referral center. The high cost of phenoxybenzamine led to high crossover to doxazosin. Randomization was halted, and a consecutive historical cohort of phenoxybenzamine patients was included for a case-control study design. The efficacy of alpha-blockade was assessed with preinduction infusion of incremental doses of phenylephrine. The primary outcomes were mortality, cardiovascular complications, and intensive care unit admission. The secondary outcomes were hemodynamic instability index (proportion of operation outside of hemodynamic goals), adequacy of blockade by the phenylephrine titration test, and drug costs., Results: Twenty-four patients were prospectively enrolled (doxazosin, n = 20; phenoxybenzamine, n = 4), and 15 historical patients treated with phenoxybenzamine were added (total phenoxybenzamine, n = 19). No major cardiovascular complications occurred in either group. The phenylephrine dose-response curves showed less blood pressure rise in the phenoxybenzamine than in the doxazosin group (linear regression coefficient = 0.008 vs 0.018, P = .01), suggesting better alpha-blockade in the phenoxybenzamine group. The median hemodynamic instability index was 14% vs 13% in the phenoxybenzamine and doxazosin groups, respectively (P = .56). The median highest daily cost of phenoxybenzamine was $442.20 compared to $5.06 for doxazosin., Conclusion: Phenoxybenzamine may blunt intraoperative hypertension better than doxazosin, but this difference did not translate to fewer cardiovascular complications and is offset by a considerably increased cost., (Copyright © 2022 AACE. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF